Abstract
Enhancing cognition before clinical symptoms of dementia.
Highlights
As the title of the special issue indicates, controversy surrounds augmentation of brain cognition in humans
An alternative approach consists of testing cognition enhancement in individuals not taking anti-Alzheimer’s disease (AD) medication, even in those without any clinical symptom of dementia
Relevant is that “there was no proof at that time—early eighties—that drugs or diet used to lower cholesterol would be the clinical equivalent of patients with spontaneously occurring low cholesterol,” meaning that statins were being developed without the certainty that lowering cholesterol by statins could be efficacious in combating atherosclerosis
Summary
As the title of the special issue indicates, controversy surrounds augmentation of brain cognition in humans. Failures on achieving efficacious anti-AD medications and the high cost of performing clinical trials make pharmaceutical companies to abandon the dementia field An alternative approach consists of testing cognition enhancement in individuals not taking anti-AD medication, even in those without any clinical symptom of dementia. A similar concern arises on thinking about the possibility to prescribe cognition enhancers under a chronically regime.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
